Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG-Connaught versus BCG-Tice after TURBT for high-risk non-muscle-invasive bladder cancer
ACTRN12611000204943Phase 3Completed
- Sponsor
- Inselspital
- Start
- Aug 1986
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BCG Connaught and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Inselspital. Primary endpoints: Tumor recurrence and Tumor progression. Started Aug 1986; status: completed.
02
Drugs
BCG Connaughtbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ACTRN12611000204943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000204943.